Consistent performance across NDA 155 and 156 reinforces the standing of Doon Defence Dreamers in India’s defence education ecosystem. Doon Defence Dreamers has reinforced its reputation in India’s de ...
The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the Fir ...
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript February 10, 2026 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.94, expectations were $0.77. Operator: Good day, ladies ...
PolyPid Ltd (PYPD) reports significant progress in clinical trials and strategic partnerships, despite facing increased expenses and net losses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results